Degarelix: clinical trials recruiting now
9
Recruiting trials
15
Conditions studied
46
US states with sites
5
Countries
FDA drug label
- FDA-approved
- Yes. Degarelix appears in the FDA drug-label database. Marketed as FIRMAGON.
FDA-approved use
FIRMAGON ® is indicated for treatment of patients with advanced prostate cancer. FIRMAGON is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer. ( 1 )
Phase breakdown
Phase 2 6
Phase 3 2
Phase 4 1
Conditions being studied
Recruiting trials involving Degarelix
- A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
- Cardiometabolic Consequences of the Loss of Ovarian Function
- ETHAN - ET for Male BC
- Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
- Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Common questions
Is Degarelix FDA-approved?
Yes, marketed as FIRMAGON.
How many recruiting trials involve Degarelix?
9 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.